| Literature DB >> 28154606 |
Abstract
Pain and urinary symptoms following colorectal cancer (CRC) surgery are frequent and carry a poor recovery. This study tested the effects of inhalation of Lavandula angustifolia Mill. (lavender) oil or linalyl acetate on pain relief and lower urinary tract symptoms (LUTS) following the removal of indwelling urinary catheters from patients after CRC surgery. This randomised control study recruited 66 subjects with indwelling urinary catheters after undergoing CRC surgery who later underwent catheter removal. Patients inhaled 1% lavender, 1% linalyl acetate, or vehicle (control group) for 20 minutes. Systolic and diastolic blood pressure (BP), heart rate, LUTS, and visual analog scales of pain magnitude and quality of life (QoL) regarding urinary symptoms were measured before and after inhalation. Systolic BP, diastolic BP, heart rate, LUTS, and QoL satisfaction with urinary symptoms were similar in the three groups. Significant differences in pain magnitude and urinary residual sense of indwelling catheters were observed among the three groups, with inhalation of linalyl acetate being significantly more effective than inhalation of lavender or vehicle. Inhalation of linalyl acetate is an effective nursing intervention to relieve pain and urinary residual sense of indwelling urinary catheters following their removal from patients who underwent CRC surgery.Entities:
Year: 2017 PMID: 28154606 PMCID: PMC5244020 DOI: 10.1155/2017/3954181
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
General characteristics of the subjects (N = 66).
| Characteristics | Control | Lavender | Linalyl acetate |
|
|---|---|---|---|---|
|
|
|
| ||
| Age (years) | 60.64 (13.83) | 61.18 (10.06) | 61 (12.52) | 0.989 |
| Gender | 0.822 | |||
| Male | 14 (63.64) | 15 (68.18) | 13 (59.09) | |
| Female | 8 (36.36) | 7 (31.82) | 9 (40.91) | |
| Smoking | 0.782 | |||
| Yes | 9 (40.91) | 11 (50) | 9 (40.91) | |
| No | 13 (59.09) | 11 (50) | 13 (59.09) | |
| Smoking period (years) | 10.95 (15.49) | 15.14 (18.07) | 8.86 (12.04) | 0.570‡ |
| Smoking amount (cigs/day) | 7.36 (10.80) | 8.18 (9.07) | 6.05 (8.40) | 0.730‡ |
| Exercise frequency (times/wk) | 0.177† | |||
| 1-2 | 2 (9.09) | 0 (0) | 2 (9.09) | |
| 3-4 | 2 (9.09) | 5 (22.73) | 3 (13.64) | |
| ≥5 | 4 (18.18) | 6 (27.27) | 12 (54.55) | |
| Alcohol drinking | 0.475† | |||
| Yes | 10 (45.45) | 14 (63.64) | 9 (40.91) | |
| No | 12 (54.55) | 8 (36.36) | 13 (59.09) | |
| Drinking amount (glasses/wk) | 0.217† | |||
| 1-2 | 5 (22.73) | 1 (4.55) | 2 (9.09) | |
| 3-4 | 0 (0) | 3 (13.64) | 1 (4.55) | |
| 5-6 | 1 (4.55) | 1 (4.55) | 2 (9.09) | |
| 7–9 | 0 (0) | 4 (18.18) | 1 (4.55) | |
| ≥10 | 4 (18.18) | 5 (22.73) | 3 (13.64) | |
| Caffeine intake (glasses/day) | 0.248† | |||
| 0-1 | 14 (63.64) | 12 (54.55) | 11 (50) | |
| 2–4 | 7 (31.82) | 9 (40.91) | 11 (50) | |
| 5-6 | 0 (0) | 1 (4.55) | 0 (0) | |
| ≥7 | 1 (4.55) | 0 (0) | 0 (0) | |
| Antihypertensives | ||||
| Yes | 7 (31.82) | 8 (36.36) | 8 (36.36) | 0.935 |
| No | 15 (68.18) | 14 (63.64) | 14 (63.64) | |
| Surgery | ||||
| Robotic | 7 (32.82) | 9 (40.91) | 7 (32.82) | 0.774 |
| Laparoscopic | 15 (68.18) | 13 (59.09) | 15 (68.18) | |
| Oral antidiabetics | ||||
| Yes | 4 (18.18) | 4 (18.18) | 3 (13.64) | >0.999 |
| No | 18 (81.82) | 18 (81.82) | 19 (86.36) | |
| Metastasis | ||||
| Yes | 6 (27.27) | 8 (36.36) | 7 (31.82) | 0.811 |
| No | 16 (72.73) | 14 (63.64) | 15 (68.18) |
Data reported as mean (standard deviation) or n (%).
Chi-square test.
Analysis of variance (ANOVA).
‡Kruskal-Wallis test.
†Fisher's exact test.
Measured variables prior to essential oil inhalation in the three groups.
| Variables | Group ( | Mean (SD) |
|
|---|---|---|---|
| VAS Pain | Control (22) | 4.48 (1.42) | 0.413 |
| Lavender (22) | 3.92 (1.51) | ||
| Linalyl acetate (22) | 4.37 (1.53) | ||
|
| |||
| sBP (mmHg) | Control (22) | 125.05 (18.40) | 0.798† |
| Lavender (22) | 128.18 (10.48) | ||
| Linalyl acetate (22) | 126.86 (16.52) | ||
|
| |||
| dBP (mmHg) | Control (22) | 74.50 (11.45) | 0.453† |
| Lavender (22) | 75.27 (6.76) | ||
| Linalyl acetate (22) | 71.86 (9.26) | ||
|
| |||
| HR (beats/min) | Control (22) | 77.73 (18.40) | 0.524 |
| Lavender (22) | 73.14 (11.67) | ||
| Linalyl acetate (22) | 72.77 (15.88) | ||
|
| |||
| Urinary residual sense score | Control (19) | 0.79 (1.55) | 0.907 |
| Lavender (18) | 1.28 (2.08) | ||
| Linalyl acetate (21) | 1.19 (1.89) | ||
|
| |||
| Total LUTS score | Control (19) | 3.74 (4.49) | 0.148 |
| Lavender (18) | 6.78 (5.84) | ||
| Linalyl acetate (21) | 5.81 (5.44) | ||
|
| |||
| Quality of life score | Control (19) | 2.32 (0.67) | 0.075 |
| Lavender (18) | 2.83 (0.86) | ||
| Linalyl acetate (21) | 2.81 (0.87) | ||
Data reported as mean (standard deviation)
VAS, visual analog scale; sBP, systolic blood pressure; dBP, diastolic blood pressure; HR, heart rate; LUTS, lower urinary tract symptoms.
Kruskal-Wallis test.
†ANOVA.
Figure 1Effects of lavender or linalyl acetate inhalation on VAS pain scores in (a) all patients, (b) patients who were not treated with antihypertensive drugs (nonhypertensives) and were treated with antihypertensive drugs (hypertensives), and (c) patients who underwent laparoscopic and robotic operations. Results are presented as mean ± standard error of the mean, with differences compared by the Kruskal-Wallis test or Wilcoxon's rank sum test. P < 0.05 versus control, P < 0.001 versus control undergoing robotic surgery, §P < 0.05 versus lavender undergoing robotic surgery, #P < 0.05, ##P < 0.01, and ###P < 0.001. VAS: visual analog scale.
Difference in total urinary symptoms and satisfaction with urination among the three groups.
| Variables | Group ( | Pretest | Posttest |
| Difference |
|
|---|---|---|---|---|---|---|
| Urinary residual sense score | Control (19) | 0.79 (1.55) | 0.16 (0.69) | 0.135 | −0.63 (1.67) | 0.540 |
| Lavender (18) | 1.28 (2.08) | 0.00 (0.00) | 0.004 | −1.28 (2.08) | ||
| Linalyl acetate (21) | 1.19 (1.89) | 0.38 (1.12) | 0.046 | −0.81 (1.69) | ||
|
| ||||||
| Total LUTS score | Control (19) | 3.74 (4.49) | 4.37 (4.86) | 0.660 | 0.63 (6.39) | 0.234 |
| Lavender (18) | 6.78 (5.84) | 3.94 (4.01) | 0.059 | −2.83 (4.69) | ||
| Linalyl acetate (21) | 5.81 (5.44) | 5.33 (7.23) | 0.727 | −0.48 (7.15) | ||
|
| ||||||
| Quality of life score | Control (19) | 2.32 (0.67) | 2.32 (0.75) | >0.999 | 0.00 (0.82) | 0.488 |
| Lavender (18) | 2.83 (0.86) | 2.50 (0.79) | 0.111 | −0.33 (0.77) | ||
| Linalyl acetate (21) | 2.81 (0.87) | 2.57 (0.87) | 0.216 | −0.24 (1.00) | ||
Data reported as mean (standard deviation).
LUTS: lower urinary tract symptoms.
Kruskal-Wallis test.